



## Advances in Human Monkeypox Vaccines Effectiveness, Safety and Hesitancy

Guest Editor:

### Dr. Abanoub Riad

1. Department of Public Health,  
Faculty of Medicine, Masaryk  
University, 625 00 Brno, Czech  
Republic

2. Institute of Health Information  
and Statistics of the Czech  
Republic (IHIS-CR), 128 01  
Prague, Czech Republic

3. Czech National Center of  
Evidence-based Healthcare and  
Knowledge Translation  
(Cochrane Czech Republic, Czech  
EBHC: JBI Centre of Excellence,  
Masaryk University GRADE  
Centre), Faculty of Medicine,  
Masaryk University, 625 00 Brno,  
Czech Republic

Deadline for manuscript  
submissions:

**20 October 2024**

### Message from the Guest Editor

The human monkeypox (HMPX) outbreak of 2022 did not only cause several thousands of cases in non-endemic countries but also triggered multi-faceted debates about epidemic preparedness, discontinuation of smallpox vaccination, effectiveness and safety of the repurposed smallpox vaccines and drugs, and public interest in (acceptance of) immunization against orthopoxviruses.

I am pleased to invite you to participate in this Special Issue which aims to delve into three main thematic areas. Firstly, the effectiveness of the repurposed smallpox vaccines that are used as pre- or post-exposure prophylaxis needs to be evaluated within the context of the ongoing outbreak, especially among high-risk groups and healthcare settings. Secondly, pre- and post-authorization safety of HMPX vaccines and antivirals should be actively monitored in order to update the current immunization guidelines in light of the best available evidence. Thirdly, vaccination acceptance and misconceptions among healthcare professionals, students, and high-risk groups are of utmost importance amid this outbreak because they may either accelerate or unnecessarily delay the task of epidemic control.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)